Executive Vice President, Research and Development, appointed


Anders Ullman has been appointed to lead Nycomed’s research and development function upon approval and completion of the deal to purchase ALTANA Pharma.

Anders Ullman has a 16 year track record of medical research and development, most recently as Senior Vice President, Research & Development, at the European biopharma company Biovitrum.

“With the head of R&D in place, the Executive Committee for the new Nycomed is set. This gives us the possibility to join ALTANA Pharma and Nycomed together as soon as all the approvals are received from authorities and shareholders,” said Håkan Björklund, Nycomed CEO.

“I have every confidence that Anders Ullman has what it takes to lead the Nycomed R&D organisation so that it fulfils its potential and makes a real difference to the needs of patients and healthcare professionals,” Håkan Björklund continues.

“The new Nycomed will be an outstanding company and I am very excited about this opportunity. I’m looking forward to start work and align the two companies’ R&D strategies in the new company next year,” said Anders Ullman who will lead the new R&D function from Konstanz, Germany.
The new Executive Committee will be effective from the closing of the deal to purchase ALTANA Pharma expected by the year end.

About the ALTANA Pharma acquisition

On 21 September 2006, Nycomed announced that it had reached an agreement to acquire ALTANA Pharma AG, the pharmaceutical business of German-based international pharmaceuticals and chemicals group, ALTANA AG.

Closing of the transaction will be subject to the approval of the shareholders of ALTANA AG and necessary antitrust clearances. Pending the final approvals, closing is expected to take place at the turn of the year. The combined group will continue under the Nycomed corporate brand name and will be headquartered in Zürich, Switzerland.

About Nycomed

Nycomed is a pharmaceutical company dedicated to meeting needs in Europe. The company provides hospital products throughout the region and general practitioner and pharmacy medicines in selected markets.

New products are sourced through licensing agreements with research companies. Here Nycomed provides late-stage clinical development, registration and marketing.

Headquartered in Roskilde, Denmark, the company employs about 3,500 people throughout Europe and Russia-CIS. Nycomed is privately owned and had a 2005 revenue of € 747.5 million.

For more information visit www.nycomed.com

About Dr. Anders Ullman

Born 1956. Physician and Clinical Pharmacologist affiliated with the University of Gothenburg. Dr. Ullman worked as Medical Manager for Upjohn in Scandinavia (1990-1991) and subsequently as Head of Human Pharmacology at Astra Draco in Lund. He was later appointed Head of Clinical R&D at Astra Draco and then Head of Clinical R&D in the area of Respiratory & Inflammation therapies at Astra Draco in Lund and Astra Charnwood in Loughborough, in the UK.

In conjunction with the AstraZeneca merger, Dr. Ullman was assigned responsibility for establishing and leading the combined global clinical development. Before joining Biovitrum in late 2004, Dr. Ullman was the Head of Bayer Pharmaceutical’s global development operations, which are based in Germany.

For further information

Håkan Björklund, CEO
Phone: +45 46 77 11 11

Christoffer Jensen, VP Communications
Phone: +45 46 77 11 12


For further information

General phone:

+41 44 555 15 10
Beatrix Benz,

phone: +41 44 555 1508
Tobias Cottmann,

phone: +41 44 555 1501

Christian B. Seidelin,

phone: +41 44 555 11 04

Related information

English PDF
Danish PDF

Top of page

Takeda Pharma